Gen Wealth Partners Inc Sells 84 Shares of Stryker Co. (NYSE:SYK)

Gen Wealth Partners Inc decreased its holdings in shares of Stryker Co. (NYSE:SYK) by 5.6% in the 4th quarter, according to its most recent Form 13F filing with the SEC. The firm owned 1,426 shares of the medical technology company’s stock after selling 84 shares during the period. Gen Wealth Partners Inc’s holdings in Stryker were worth $513,000 as of its most recent SEC filing.

Several other hedge funds have also bought and sold shares of SYK. Kohmann Bosshard Financial Services LLC purchased a new position in Stryker during the 4th quarter valued at $25,000. Rakuten Securities Inc. boosted its stake in shares of Stryker by 618.2% during the 4th quarter. Rakuten Securities Inc. now owns 79 shares of the medical technology company’s stock worth $28,000 after acquiring an additional 68 shares during the last quarter. Centricity Wealth Management LLC purchased a new stake in shares of Stryker in the fourth quarter worth $30,000. BankPlus Trust Department bought a new position in Stryker in the 4th quarter worth $33,000. Finally, VSM Wealth Advisory LLC bought a new stake in Stryker during the fourth quarter valued at about $36,000. 77.09% of the stock is currently owned by institutional investors.

Insider Activity at Stryker

In related news, Director Ronda E. Stryker sold 200,000 shares of the business’s stock in a transaction that occurred on Tuesday, May 6th. The stock was sold at an average price of $376.96, for a total transaction of $75,392,000.00. Following the sale, the director now owns 3,417,326 shares of the company’s stock, valued at $1,288,195,208.96. The trade was a 5.53 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Allan C. Golston sold 2,458 shares of the stock in a transaction on Tuesday, February 18th. The shares were sold at an average price of $383.07, for a total value of $941,586.06. Following the transaction, the director now directly owns 14,895 shares of the company’s stock, valued at approximately $5,705,827.65. The trade was a 14.16 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Company insiders own 5.90% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities analysts have commented on SYK shares. JPMorgan Chase & Co. increased their price objective on shares of Stryker from $420.00 to $445.00 and gave the company an “overweight” rating in a research report on Wednesday, January 29th. Evercore ISI lowered their price target on Stryker from $400.00 to $390.00 and set an “outperform” rating for the company in a research report on Friday, May 2nd. Wells Fargo & Company boosted their price objective on shares of Stryker from $427.00 to $435.00 and gave the company an “overweight” rating in a research report on Wednesday, January 29th. Citigroup reaffirmed a “buy” rating and set a $450.00 price target on shares of Stryker in a research note on Wednesday, February 26th. Finally, BTIG Research set a $403.00 price objective on shares of Stryker and gave the stock a “buy” rating in a research note on Monday, April 14th. Five analysts have rated the stock with a hold rating and fifteen have given a buy rating to the stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $427.05.

Stryker Stock Down 0.4 %

Shares of NYSE:SYK opened at $380.87 on Friday. Stryker Co. has a 1-year low of $314.93 and a 1-year high of $406.19. The company’s fifty day moving average is $365.47 and its two-hundred day moving average is $374.38. The company has a debt-to-equity ratio of 0.59, a quick ratio of 1.32 and a current ratio of 1.95. The stock has a market capitalization of $145.37 billion, a price-to-earnings ratio of 49.08, a price-to-earnings-growth ratio of 2.93 and a beta of 0.93.

Stryker (NYSE:SYK) last released its quarterly earnings data on Thursday, May 1st. The medical technology company reported $2.84 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.73 by $0.11. The business had revenue of $5.87 billion during the quarter, compared to analyst estimates of $5.68 billion. Stryker had a return on equity of 23.58% and a net margin of 13.25%. The business’s revenue for the quarter was up 11.9% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $2.50 EPS. Equities analysts anticipate that Stryker Co. will post 13.47 EPS for the current year.

Stryker Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Thursday, July 31st. Stockholders of record on Monday, June 30th will be paid a $0.84 dividend. The ex-dividend date is Monday, June 30th. This represents a $3.36 annualized dividend and a dividend yield of 0.88%. Stryker’s payout ratio is 45.41%.

Stryker Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.